Treatment Combination Improves Survival in EGFR-positive Lung Cancer
Adding chemotherapy to targeted therapy improves outcomes for people with advanced EGFR-positive non-small cell lung cancer.
Progress Against Cancer
Adding chemotherapy to targeted therapy improves outcomes for people with advanced EGFR-positive non-small cell lung cancer.
Since 1993, the American Association for Cancer Research (AACR) has invested more than $542 million in grants to sustain the pipeline of cancer researchers and accelerate breakthroughs for patients. The second annual AACR Grantee...
A look at recent research on determining breast cancer risk, the impact of lifestyle changes on cancer risk, and why screening is important.
The FDA has approved the menin inhibitor revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in certain adult and pediatric patients 1 year and older. The U.S. Food and...
COVID vaccines may improve immunotherapy effects, and a drug combination reduces the risk for death in bladder cancer.
In October 2025, AACR's journals editors highlighted studies on the anticancer function of an Alzheimer’s-related protein, small-molecule-drug conjugates, and more.
The FDA approved the BCMA-targeted antibody-drug conjugate belantamab mafodotin-blmf as part of a combination therapy for adults with refractory or recurrent multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved belantamab mafodotin-blmf...
The AACR Conference on the Science of Cancer Health Disparities explored the field's evolving landscape, including funding and and long-term impact.
Frank McCormick, PhD, FAACR, reflected on a career chasing the notorious RAS oncogene that earned him the inaugural Stephenson Global Prize.
The psychological toll of cancer can have an impact on patients’ mental health and put them at an increased risk of harm.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More